Drug Trial Radar · NCT04362813
Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
Last checked: Nov 20, 2026Latest source record: Jan 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
454
Actual
Start
Apr 30, 2020
Primary completion
Sep 16, 2020
Study completion Dec 22, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 27, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia and cytokine release syndrome (CRS).
Conditions
- Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Interventions
CanakinumabDrug
Canakinumab 450 mg for body weight 40-\<60 kg, 600 mg for 60-80 kg or 750 mg for \>80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
PlaceboDrug
250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants Who Survived Without Requiring Invasive Mechanical Ventilation From Day 3 to Day 29, Primary AnalysisTime frame: Day 3 to Day 29
Locations
39 sites in 6 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Glendale, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
San Francisco, California
Novartis Investigative Site
Chicago, Illinois
Novartis Investigative Site
Baltimore, Maryland
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Boston, Massachusetts
Novartis Investigative Site
Brooklyn, New York
Novartis Investigative Site
Chapel Hill, North Carolina
Novartis Investigative Site
Cleveland, Ohio
Novartis Investigative Site
Philadelphia, Pennsylvania
Novartis Investigative Site
Houston, Texas
Novartis Investigative Site
Richmond, Virginia
Novartis Investigative Site
Tacoma, Washington
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Bergamo, BG, Italy
Novartis Investigative Site
Cona, FE, Italy
Novartis Investigative Site
Barnaul, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Moscow, Russia
Novartis Investigative Site
Ryazan, Russia
Novartis Investigative Site
S-Petersburg, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Saint Petersburg, Russia
Novartis Investigative Site
Sestroretsk, Russia
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
San Sebastián de los Reyes, Madrid, Spain
Novartis Investigative Site
Barnet, United Kingdom
Novartis Investigative Site
Coventry, United Kingdom
Novartis Investigative Site
Leeds, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.